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The nicotinic system is involved in the pathophysiology of schizophrenia. However, very lit-
tle is known about its genetic basis and how it relates to clinical symptoms and potentially
pharmacological intervention. Here, we investigated five single nucleotide polymorphisms
(SNPs) [rs3826029] [rs2337506] [rs982574] [rs904952] [rs2337980] of the cholinergic nico-
tinic receptor gene, alpha 7 subunit (CHRNA7) and their association to schizophrenia. We
found an association with rs904952 (p=0.009) in a German sample of 224 schizophrenic
patients and 224 healthy control subjects. The same trend was shown in an independent
Georgian sample of 50 schizophrenic patients, 57 first order unaffected relatives, and 51
healthy controls. In addition, visual backward masking (VBM), a sensitive test for early visual
information processing, was assessed in the Georgian sample. In line with prior studies,
VBM performance deficits were much more pronounced in schizophrenic patients and their
unaffected relatives compared to healthy controls (schizophrenic patients: 156 ms; unaf-
fected relatives: 60 ms; healthy controls: 33 ms). VBM was strongly correlated with SNP
rs904952 (H[2]=7.3, p=0.026). Our results further support the notion that changes in the
nicotinic system are involved in schizophrenia and open the avenue for pharmacological
intervention.
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INTRODUCTION
Schizophrenia is a severe disease affecting patients’ professional
and social life. Schizophrenia is strongly influenced by genetic
factors. A large variety of candidate genes have been identified
in the last years with controversial results (1–4). A major rea-
son for the contradicting findings is the large number of genetic
and environmental factors contributing to the pathophysiology of
schizophrenia (5).
The nicotinic system has been found to play an important role
in the pathogenesis of schizophrenia (6–8). Evidence for a relation-
ship between the cholinergic nicotinic receptor alpha 7 subunit
(CHRNA7) and schizophrenia was shown by both association (9–
11) and linkage studies (12–14), although with mixed results (5,
15). A deletion of 15q13.3, the chromosomal location of CHRNA7,
was identified in schizophrenic patients (16–18) together with
deficiencies in cholinergic transcription in the corpus callosum
(7) and reductions of the receptor protein in the hippocampus,
cortex, and thalamus (6, 19, 20). Schizophrenic patients are often
heavy smokers, which may be a way of self medication (21–24).
Although several lines of evidence point to the nicotinic system,
current drugs applied in schizophrenic patients largely neglected
this system.
Visual information processing is disturbed in schizophrenic
patients. For example, sensorimotor gating has been found to be
impaired in schizophrenic (25) and bipolar patients with psychotic
mania (26). Visual backward masking (VBM) and particularly the
shine-through masking paradigm are reliable methods of mea-
suring deficits of visual processing (27–31). The shine-through
paradigm showed impaired masking in schizophrenic patients
and their first-degree relatives (27) compared to healthy controls.
Because of this and other findings, the shine-through masking
paradigm is a potential endophenotype of schizophrenia (27). We
have recently argued that these deficits are not of primary visual
nature but are related to deficient mechanisms of target enhance-
ment (32). Neural activity of low contrast or briefly presented
elements needs to be enhanced to counteract overwriting of sub-
sequently presented stimuli. We postulated that the cholinergic
system is one candidate of target enhancement which may be
deficient in schizophrenic patients (32). These observations are
in line with other studies which showed that the nicotinic sys-
tem is involved in the regulation of visual information processing
(33–36) including sensory gating and P50 suppression (9, 37).
Interestingly, an alpha 7 receptor agonist improved both p50 gat-
ing function and cognition in schizophrenic patients (38). The
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cholinergic nicotinic receptor alpha 4 subunit gene (CHRNA4)
has been found to modulate both auditory and visual informa-
tion processing (39). For this reason, we targeted the cholinergic
system and determined the influence of five single nucleotide poly-
morphisms (SNPs) on the diagnosis of schizophrenia in a German
sample of 224 schizophrenic patients and 224 healthy controls. We
further investigated these effects in a smaller Georgian sample with
50 schizophrenic patients, 57 first-degree unaffected relatives, and
51 healthy controls and determined VBM in addition. The SNPs
where selected according to ABI SNP browser selection1.
METHODS
PARTICIPANTS
Data were collected from a German sample of 224 schizophrenic
patients and 224 healthy controls. All subjects were of Central
European descent. Group characteristics are depicted in Table 1.
The diagnosis of schizophrenia was made according to DSM-IV
criteria. Severity of psychopathology was assessed by an experi-
enced clinician (I. Puls) using the Positive and Negative Symptom
Scale (PANSS), the Scale for the Assessment of Positive Symptoms
(SAPS), and the Scale for the Assessment of Negative Symptoms
(SANS) (40, 41). Patients were on various neuroleptic agents,
including haloperidol, olanzapine, risperidone, amisulpride, que-
tiapine, aripiprazole, ziprasidone. Individuals with present or life
time alcohol and/or drug dependency as well as other psychi-
atric and neurological diseases were excluded from the study.
All patients were recruited at the Department of Psychiatry and
Psychotherapy, Charité, in Berlin, Germany. For comparison, 224
healthy controls were recruited from the general population. All
controls were free of any axis 1 and 2 or major somatic disorders.
For evaluation of VBM, we repeated the experiment in a Geor-
gian sample including 50 schizophrenic patients, 57 first order
relatives, and 51 healthy control subjects. All subjects were of
Central European descent recruited at the Asatiani Psychiatric
Institute in Tbilisi, Georgia. The diagnosis of schizophrenia was
made according to DSM-IV criteria. Psychopathology was assessed
using SANS and SAPS by an experienced clinician (27). Individu-
als with alcohol and/or drug dependency, as well as other diseases
that could affect the mental state of the subject were excluded from
1http://marketing.appliedbiosystems.com/mk/get/snpb_landing
the study. All relatives and controls were free of any axis 1 and
2 disorder, which was confirmed by the Schizotypal Personality
Questionnaire (SPQ).
PROCEDURE
The study was approved by the local ethic committees in Berlin
and Tbilisi and was performed in accordance with the Declaration
of Helsinki (1964). Approvals were obtained from the Georgian
National Council on Bioethics (Meeting Statement of Ethical
Committee of Institute of Postgraduate Medical Education and
Continuous professional Development N 9/07) and the ethics
committee of the University Hospital Charite, Berlin (Ethikkom-
mission, Ethikausschuss 1 Campus Charite – Mitte, application
number: EA1/115/10). All participants gave informed written con-
sent prior to their participation. All participants received a clinical
interview, evaluating the present medical state, and prior dis-
eases. In schizophrenic patients, the degree of psychopathology
was assessed. In all study participants, 30 ml of whole blood was
taken for genetic analysis.
In the Georgian sample, visual acuity was determined by the
Freiburg Visual Acuity Test (FrACT) for each eye separately. A
value of at least 0.8 for at least one eye was required. Afterward,
the shine-through masking paradigm was performed.
THE SHINE-THROUGH BACKWARD MASKING PARADIGM
The shine-through backward masking paradigm was performed
in the Georgian sample only. Subjects observed the stimuli from
a distance of 3.5 m in a room illuminated dimly by a background
light (around 0.5 lx). A pixel of the screen (19′′) comprised about
18′′ (arc sec) at this distance. Stimuli were white on a black back-
ground. Stimulus luminance was 100 cd/m2. Refresh rate of the
screen was 100 Hz. Conditions were tested in blocks of 80 trials.
Vernier
A vertical vernier is composed of two vertical bars which are
slightly offset either to the left or right. The length of a bar was
10′ (arc min). The bars were separated by a small gap of 1′. Thus,
altogether a vernier was about 21′ long. In each trial, the vernier
offset direction was chosen randomly. In a binary task, observers
were asked to indicate this offset direction (left/right). Errors were
indicated by an auditory signal.
Table 1 | Demographics.
Variable German sample Georgian sample
Patients Controls Statisticsa Patients Relatives Controls Statisticsa
Participants (#) 224 224 NA 50 57 51 NA
Male (%) 50.7 58.0 2.3 (0.13) 76 45.6 60.8 10.3 (0.006)
Age (mean) 37.0 40.8 3.33 (0.07) 34 35 34 0.16 (0.8)
Education in years (mean) – – – 13 14 16 7.5 (0.001)
Visual acuity (mean VA by FrACT) – – – 1.5 1.7 1.7 2.5 (0.08)
aFor categorical data (gender), Chi-square statistics are reported. For visual acuity, age, and education F statistic is shown. In study participants from Germany, only
basic clinical and psychiatric information was assessed, whereas the Georgian sample was characterized in more detail.
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FIGURE 1 | Shine-through paradigm. (A) A vernier comprised two vertical
bars which were slightly offset to the left (not shown) or right (shown here).
Observers indicated this offset direction. For each observer, we determined
the individual vernier duration (VD) for which 75% correct responses were
reached. (B) In the next step, this individual vernier duration was used for
each observer. The vernier offset was fixed at 71′′ (arc sec). This vernier was
followed by a blank screen (ISI) and a grating comprised of 25 aligned
verniers, i.e., verniers without offset. SOA=VD+ ISI.
Vernier duration
First, we tested unmasked verniers, i.e., without a grating. We
aimed to find the shortest VD, for which observers could per-
form vernier offset discrimination reliably (43) (Figure 1A). For a
given VD, we determined adaptively (44) whether offset discrimi-
nation was below 40′′ (arc sec). We started with VDs of 150 ms and
reduced durations blockwise until offset discrimination was above
40′′. Observers with VDs longer than 100 ms were excluded at this
stage to ensure that all observers were rather “good” performers
(sensitivity should not be boosted by bad “performers”).
Masking
In the masking experiment, we presented the vernier with the
individual duration for each observer. Vernier offset size was set
to 71′′. First, an inter-stimulus interval (ISI) followed the vernier,
and then, a masking grating (Figure 1B). The grating comprised 25
aligned verniers, i.e., without offset, of the same length and width
as the target vernier. The horizontal distance between grating ele-
ments was about 3.33′. The vernier and the central element of the
grating appeared always in the middle of the screen. The grating
lasted for 300 ms. We adaptively assessed the target-mask stimu-
lus onset asynchrony (SOA) to yield a performance level of 75%
correct responses for the vernier (SOA=VD+ ISI). In this part of
the experiment, we varied the ISI, not the vernier offset size. The
adaptive strategy started with an SOA of 200 ms that was either
decreased or increased to find the individual threshold. A value of
450 ms was recorded if observers were unable to reach 75% correct
responses for an SOA of 400 ms (45). We did not measure accuracy
for different SOAs as it was done in most other masking studies
in schizophrenia research, but we determined performance in one
block.
GENETIC ANALYSIS
For genetic analysis, approximately 30 ml EDTA blood samples
were collected from each participant in both study cohorts.
Genetic analysis for both chorts was performed in the Genetic
Table 2 | Single nucleotide polymorphisms genotyped within the
CHRNA7 gene.
CHRNA7
SNPs
Position MAF Alleles Location Reference
rs3826029 3112042 0.409 A/G 5′near gene Iwata et al. (42)
rs2337506 3136624 0.455 G/A Intron 2 Iwata et al. (42)
rs982574 3164580 0.215 G/C Intron 2 Iwata et al. (42)
rs904952 3209302 0.382 C/T Intron 4 Iwata et al. (42)
rs2337980 3234753 0.416 T/C Intron 4 Iwata et al. (42)
The characteristics of SNPs are derived from the NCBI database. Contig posi-
tion indicates the exact position of each SNP at contig NT_010194.16/17. MAF
(minor allele frequency) is derived from 1000 Genome phase 1 genotype data
from 1094 worldwide individuals, released in the May 2011 dataset. The minor
allele is depicted in the first position. Location indicates the SNP position within
the CHRNA7 gene.
Section, Department of Psychiatry and Psychotherapy, CCM,
Charité University Medicine, Berlin. From the blood samples,
DNA was extracted using standard procedures. Five SNPs of the
cholinergic nicotine receptor gene, alpha 7 subunit (CHRNA7)
were genotyped in the German and Georgian samples (for SNP
details see Table 2). All SNPs have tagging function selected in
consideration of both genetic and physical coverage that was based
on Applied Biosystems SNPbrowser™ Software v3.5. Informa-
tion about physical location and heterozygosity index of SNPs
was derived from the University of California Santa Cruz (UCSC)
Human Genome Browser2 and the National Center of Biotechnol-
ogy Information (NCBI) SNP database3. Primers were designed
for amplification of relevant DNA regions by polymerase chain
reaction (PCR). PCR products were cut by allele specific restriction
enzymes and visualized after gel electrophoresis (for PCR details
see Table 3). Quality control was performed by in-gel standards
to confirm expected fragments sizes and by random duplication
of control samples for each plate. Primer information and spe-
cific assay conditions are available on request. Interpretation of
gel electrophoresis was done by two independent investigators.
STATISTICAL ANALYSIS
For statistical analysis, SPSS v. 16.0 was used. We measured the
association of genotype and diagnosis on both samples. In the
Georgian sample, we additionally measured the SOA differences
between the groups and the differences of SOA’s between the car-
riers of different genotypes. To test for a relationship between
categorical variables, such as allele variants (three categories) and
study groups (three categories: patients, relatives, and controls),
a crosstabulation analysis using Chi-square statistics was applied.
For the analysis of categorical data such as gender, the Chi-square
test was used. For quantitative, normally distributed data, F statis-
tics was used. For quantitative, non-normally distributed data [like
shine-through data (SOA)] Kruskal–Wallis and Mann–Whitney
tests were used. The power analysis was conducted using software
2http://www.genome.ucsc.edu/cgi-bin/hgGateway
3http://www.ncbi.nlm.nih.gov/sites/entrez
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Table 3 | Amplification and restriction details of SNPs studied.
CHRNA7 SNPs Genotype Forward primer Reverse primer Product size Restriction products Enzyme t° GFR in%
DE GEO
rs3826029 A/G gtgaatccagttcagctgtc gtgactgagcttgactgtac 243 243, 137, 106 Afl II 56 0.4 0
rs2337506 G/A gccttggagtcacagctc gcaatttcctactcctcgtc 255 255, 170, 85 BssSI 56 0.4 0
rs982574 G/C cataacttagaatactcaacaag gttgccaccacatctaccttc 164 164, 86, 78 Mnl I 56 0.9 0.6
rs904952 C/T caaattggttaatttctgttcctAg ccatggaaaacaggatgagtg 134 134, 109, 25 AluI 56 0 0
rs2337980 T/C ctgtcctccggtatctgtg cagtcacttctgtgtctaag 271 (193, 78), 156, 37 Bsr I 56 0.2 0.6
Forward and reverse primers, as well as product sizes, restriction products, and restriction enzymes are shown in the table. In a forward primer of rs904952 C
has been mutated into A, it is shown as captial letter. BsrI was a double cutter, therefore additional restriction product emerged (shown in brackets). t°, annealing
temperature; GFR, genotyping fail rate; DE, German sample; GEO, Georgian sample.
Table 4 | Hardy–Weinberg equilibrium in German and Georgian
samples.
SNP Genotype HWE p-value
German Georgian
rs3826029 A/G 0.578 0.377
rs2337506 G/A 0.899 0.946
rs982574 G/C 0.146 1.0
rs904952 C/T 0.005 0.632
rs2337980 T/C 0.566 0.513
G*Power version 3.1.3 (46). We expected an effect size of approx-
imately 0.3 (Cramer’s V). A sample size of n= 448 is sufficiently
large to detect an effect size of 0.3 (Cramer’s V) with a power
larger than 80% (1-beta= 0.858) assuming alpha= 0.01. Hardy–
Weinberg equilibrium (HWE) and linkage disequilibrium (LD)
were calculated with Haploview version 4.2 (47, 48). Details on
HWE, as well as allele and genotype frequencies for each sam-
ple are given in Tables 4, 5, and 6. Details on LD are depicted in
Figures 2A,B. Tagging SNPs were defined by Applied Biosystems
SNPbrowser™ Software v3.5.
RESULTS
DEMOGRAPHICS
In the German sample, age (p= 0.069) and gender (p= 0.129)
did not differ significantly between controls and patients. In the
Georgian sample, groups also did not differ significantly for age
(F[2,155]= 0.168; p= 0.8). But gender [χ2(2)= 10.3; p= 0.006]
and education (F[2,155]= 7.5; p= 0.001) were significantly dif-
ferent in the Georgian sample, with fewer females in the patient
group and patients having poorer education compared to con-
trols (Table 1). However the difference between males and females
on VBM performance did not differ significantly (U = 208.5,
p= 0.66).
CHRNA7 AND THE DIAGNOSIS OF SCHIZOPHRENIA
In the German sample, we found an association of CHRNA7
with the diagnosis of schizophrenia. In SNP rs904952, the T
allele was more frequently expressed in schizophrenic patients
compared to controls [χ2(1)= 6.37; p= 0.009] (Table 6). The
p-value remained significant after Bonferroni correction for five
SNPs (0.05/5= 0.01). In the Georgian sample, a relation between
genetic variants in the CHRNA7 gene and the diagnosis of schizo-
phrenia was found. In all of the five SNPs, including rs904952 and
rs2337980 located in intron 4 of the CHRNA7 gene, the distribu-
tion of at least one allelic variant showed a pattern were relatives
lie in between of patients and controls. The differences between
the groups, however, did not reach significance likely because of
the small sample size (Table 6; Figures 3A–E).
STIMULUS ONSET ASYNCHRONY
In line with previous studies (9, 27), we found significant dif-
ferences in visual masking between patients, their first order
relatives, and controls in the Georgian sample with the longest
SOA for schizophrenic patients (156 ms), followed by the unaf-
fected relatives (60 ms), and controls (33 ms) (H[2]= 68.3,
p< 0.0001; Figure 4). Within the patient group, there was no
significant difference between subjects taking the anticholiner-
gic agent trihexyphenidyl and those who did not. Effects of
other neuroleptic drugs have not been evaluated because of small
sizes.
CHRNA7 AND SOA
In the Georgian sample, we found an association of the CHRNA7
gene with SOA level, with again the T allele of rs904952 as the
risk variant. In the patient group, a significant effect of rs904952
on the SOA was found (H[2]= 7.3, p= 0.026; Figure 5). Patients
with the T/T genotype performed significantly worse than carriers
of C/T and C/C. We used the Mann–Whitney test to calculate the
difference between the VBM performance of T/T and C/C carriers.
The difference was statistically significant (U = 5, p= 0.021) with
an effect size of r =−0.48. No such effect was observed in healthy
relatives or controls. Furthermore, no significant influence of any
other SNP on the SOA was found.
DISCUSSION
We found an association of the cholinergic nicotinic receptor gene
alpha 7 subunit (CHRNA7) with schizophrenia. Particularly one
SNP (rs904952) in intron 4 seems to be important: T allele car-
riers were more often among schizophrenic patients compared
to healthy controls in the German sample. Similar results were
found in the Georgian sample but data did not reach significance,
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Table 5 | Genotype frequencies in German and Georgian samples.
rs3826029 rs2337506 rs982574 rs904952 rs2337980
A/A A/G G/G G/G G/A A/A G/G G/C C/C C/C C/T T/T T/T T/C C/C
GEORGIAN
Whole 0.089 0.361 0.551 0.449 0.437 0.114 0.025 0.266 0.703 0.127 0.494 0.380 0.367 0.500 0.127
Patients 0.040 0.360 0.600 0.480 0.460 0.060 0.060 0.240 0.700 0.060 0.560 0.380 0.480 0.400 0.120
Relatives 0.070 0.421 0.509 0.456 0.439 0.105 0.018 0.246 0.719 0.088 0.491 0.421 0.351 0.474 0.175
Controls 0.157 0.294 0.549 0.412 0.412 0.176 0 0.314 0.686 0.235 0.431 0.333 0.275 0.627 0.078
GERMAN
Whole 0.025 0.295 0.676 0.563 0.375 0.058 0.040 0.210 0.777 0.201 0.567 0.232 0.225 0.513 0.259
Patients 0.022 0.317 0.661 0.558 0.393 0.049 0.040 0.246 0.741 0.152 0.638 0.210 0.210 0.554 0.237
Controls 0.027 0.272 0.692 0.567 0.357 0.067 0.040 0.174 0.813 0.250 0.496 0.254 0.241 0.473 0.281
Genotype frequencies for each SNP in both samples and in each group of these sample.
Table 6 | Association of CHRNA7 with diagnosis in German and Georgian samples.
Minor/major Georgian sample χ2 p-Value German sample χ2 p-Value
MAF MAF
Patients Relatives Controls Patients Controls
rs3826029 A/G 0.220 0.281 0.304 5.84 0.212 0.181 0.164 1 0.606
rs2337506 G/A 0.290 0.325 0.382 3.47 0.482 0.246 0.248 1 0.606
rs982574 G/C 0.180 0.143 0.157 4.46 0.347 0.128 0.092 3.46 0.177
rs904952 C/T 0.340 0.333 0.451 8.85 0.072 0.471 0.495 6.73 0.009
rs2337980 T/C 0.320 0.412 0.400 7.74 0.101 0.487 0.477 2.75 0.252
Association of CHRNA7 polymorphisms with the diagnosis in German and Georgian samples. Showing the genotype with minor allele in the first position, MAF,
minor allele frequencies; χ2, Chi-square value; p, significance.
FIGURE 2 | Linkage disequilibrium analysis in German (A) and
Georgian (B) samples. The strength of LD is determined as Lewontin’s
D′. In the German sample the SNPs rs3826029 and rs2337506 showed
high linkage with D′ of 0.97. In the Georgian sample, rs3826029 and
rs2337506 with D′0.94 and rs3826029 and rs982574 with D′ of 0.89 were
in high linkage disequilibrium.
probably due to the small sample size. Gault et al. (49) showed
that six different CHRNA7 transcripts are generated in the human
brain by alternative splicing of exons 3 through 5. This could be
at least partly directed by sequence variations in intron 4, explain-
ing the major effect of the genetic variations in our study. Our
results further support the significance of the nicotinic system as
www.frontiersin.org October 2013 | Volume 4 | Article 133 | 5
Bakanidze et al. CHRNA7 associated with schizophrenia and VBM
FIGURE 3 | Allelic variants of the five SNPs (rs3826029 (A), rs904952
(B), rs2337506 (C), rs2337980 (D), rs982574 (E)) of patients,
first-order relatives, and healthy controls. In all of the five SNPs, for
at least one allelic variant the count for relatives is in between patients
and controls. However, the differences between groups are not
statistically significant.
an important pathway in schizophrenia which may be the target
for pharmacological intervention.
Our findings are in line with the majority of prior studies in
this field. Case-control (9–11) and family (13, 14, 50–53) stud-
ies found a positive relationship between polymorphisms in the
CHRNA7 gene and schizophrenia. Most of these studies inves-
tigated microsatellites as genetic markers. At the moment of
conducting the present study, there were no SNPs reported to
be associated with schizophrenia. Later Stephens et al. (11) and
Stephens et al. (54) found three SNPs, which were significantly
associated witch diagnosis of schizophrenia. Fan et al. (55) con-
ducted both case-control as well as family studies in a Chinese
population and found no relationship between schizophrenia and
D15S1360, the dinucleotide microsatellite marker previously iden-
tified in several association and linkage studies positively associ-
ated with schizophrenia. Iwata et al. (42) investigated 11 SNPs
and three microsatellites, including D15S1360 and rs904952, in
Chinese patients and controls and found no significant associ-
ation between polymorphisms and schizophrenia. In addition,
publication bias has to be taken into account.
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FIGURE 4 | Mean SOA in milliseconds for each Georgian group.
Schizophrenic patients (n=50) perform worse than healthy relatives
(n=57) and controls (n=51), SD=81.7, p<0.001.
FIGURE 5 | Stimulus onset asynchrony’s of the different genotype
carriers of SNP rs904952 in the Georgian patient group. SD= 95.1,
p=0.026.
It is known for more than half century that visual information
processing is impaired in schizophrenic patients (25, 26, 30, 31,
56). Whereas performance deteriorates also in healthy observers,
the deterioration is much more pronounced in schizophrenic
patients (57–59). Visual masking deficits have been proposed
for decades to be a vulnerability marker for schizophrenia (60–
64). Evidence comes from studies showing that also unaffected
siblings of patients show masking deficits compared to controls
(65–68), likewise adolescents with psychosis adolescents (69–72),
and that masking deficits are rather constant for more than year in
schizophrenic patients (73, 74). A particularly sensitive masking
paradigm is the shine-through effect, revealing spatio-temporal
information processing at the brink of human visual resolution
in healthy human observers (75, 76) and schizophrenic patients
(27–31). In a previous study, we have shown that the shine-
through paradigm is a particular sensitive VBM technique which
outperforms classical cognitive tests such as the CPT and the
WCST (VBM sensitivity: 87%, specificity: 89%) (27). Moreover,
the shine-through masking paradigm meets the practicability and
explicability criteria proposed by Turetsky et al. (77). It is easy and
fast to apply, and independent of culture, education, and gender.
As in previous research (27), the present study also identified
significant performance differences between patients, relatives,
and controls in the Georgian sample. In addition, we found a
robust association of SNP rs904952 with VBM, the same SNP that
was also found to be associated with schizophrenia in the German
sample. This finding supports the important role of the nicotinic
system in the pathophysiology of schizophrenia and related clini-
cal parameters such as VBM performance. It needs to be evaluated
if drugs affecting the nicotinic system influence VBM.
In our study, the positive association between CHRNA7 and
VBM was only found in patients but not in the healthy relatives as
we may have expected it from a vulnerability marker. This result
is likely due to the small sample size but may also be explained by
additional genetic or non-genetic components not present in the
relatives. With CHRNA7 we may have identified one important
component in the pathophysiology of schizophrenia. However,
other factors are certainly necessary. It is interesting, and very
much at the heart of the endophenotype concept, thatVBM deficits
were significantly associated with mutations in the cholinergic sys-
tem even though there was no significant association with the
diagnosis of schizophrenia.
There are limitations with our study. None of the GWAS stud-
ies so far could confirm a single candidate gene for schizophrenia
although statistical power of these studies is usually considerably
larger than in conventional association studies (78, 79). There-
fore, the association of CHRNA7 with schizophrenia needs to
be carefully followed up. In addition, unknown confounding fac-
tors may lead to a hidden stratification bias. The significant SNP
rs904952 is not in HWE in the German sample. This might be
due to sampling procedures since inclusion criteria required only
one generation of Central European descent prior to the partic-
ipant. Particularly in Berlin with strong migration, this might
have led to a partly inhomogeneous sample. Another limitation
of our VBM study is the small sample size, although a signifi-
cant effect with such a small sample size argues rather for the
reliability of the findings. Still, the results on VBM need to be
replicated in an independent and larger sample. In addition, stud-
ies are needed to investigate the expression of CHRNA7 transcripts
in brains of schizophrenic patients to identify the specific risk
domain in the gene. Goghari et al. found an association of back-
ward masking deficits with the COMT Val158Met in schizophrenic
patients (80). Hence, future research has to evaluate other promis-
ing candidate genes of schizophrenia and their common impact
on VBM.
In summary we found a positive association between a poly-
morphism of the CHRNA7 gene and schizophrenia. In the smaller
Georgian sample the same trend was observed. In line with prior
studies, VBM with the shine-through masking paradigm showed
www.frontiersin.org October 2013 | Volume 4 | Article 133 | 7
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profound deficits in schizophrenic patients and, to a lower extent,
in their healthy first-degree relatives. In addition, we have shown
that VBM has a genetic component that runs in parallel with the
diagnosis of schizophrenia.
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